Diabetic therapeutic market forecast
Technavio’s market research analysts predict the global diabetic therapeutic market to grow steadily during the forecast period and post a CAGR of more than 7% by 2021. This industry research report identifies the increasing focus on the self-management of diabetes to be one of the major factors that will have a positive impact on the growth of this market in the coming years. With the recent years witnessing an increase in number of people diagnosed with type 1 diabetes, there has been considerable increase in the adoption of insulin delivery systems. Focusing on skipping the need to schedule appointments and reduce expenses for clinical visits, increases the adoption of insulin delivery systems, where individuals use insulin injections at home under the guidance of a physician. This led to the introduction of insulin pens, pumps, and jet injectors, which, in turn, will drive the growth of the diabetic therapeutics market.
Get A Free Sample
In terms of geographical regions, the Americas will be the major revenue contributor to the diabetic therapeutics market throughout the predicted period. The increasing prevalence of diabetes in countries such as the US, which provides opportunities for vendors to develop new, more efficient, and safer drugs will be the major factor driving market growth in this segment.
Diabetic therapeutic market value: Competitive landscape and key vendors
Characterized by the presence of numerous small and large-scale vendors, the diabetes treatment market appears to be highly competitive. The market is dominated by the major players such as AstraZeneca, Novo Nordisk, Merck, Eli Lilly, and Sanofi who are competing against each other to lead the market. The market also consists of a number of local manufacturers in various countries and will also witness the entry of several new players, which will further intensify the level of competition in the market. To increase their revenue shares and improve market position, vendors are focusing on strategic alliances which will help them in marketing and manufacturing drugs.
The leading vendors in the market are
- AstraZeneca
- Eli Lilly
- Merck
- Novo Nordisk
- Sanofi
Segmentation by type of disease and analysis of the diabetic therapeutic market
During 2016, the type 1 diabetes segment accounted for the major shares and dominated the market. The increase in the global population diagnosed with type 1 diabetes and the rising awareness of the disease will be major factors aiding the growth of this market segment in the coming years.
Segmentation by drug class of disease and analysis of the diabetic therapeutic market
- Insulin therapies
- Non-insulin therapies
Insulin therapies are mostly adopted for the most advanced stage of diabetes and are used to compensate for the inadequate production of endogenous insulin. According to the diabetes treatment market research and analysis, the insulin therapies segment accounted for the major shares and dominated the market during 2016.
Want a bigger picture? Try a FREE sample of this report now!
See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.
Key questions answered in the report include
- What will the market size and the growth rate be in 2021?
- What are the key factors driving the global diabetic therapeutic market?
- What are the key market trends impacting the growth of the global diabetic therapeutic market?
- What are the challenges to market growth?
- Who are the key vendors in the global diabetic therapeutic market?
- What are the market opportunities and threats faced by the vendors in the global diabetic therapeutic market?
- Trending factors influencing the market shares of the Americas, APAC, and EMEA.
- What are the key outcomes of the five forces analysis of the global diabetic therapeutic market?
Technavio also offers customization on reports based on specific client requirement.
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
- Market overview
- Top-vendor offerings
PART 03: Market research methodology
- Research methodology
- Economic indicators
PART 04: Introduction
PART 05: Disease overview: Diabetes
- Diagnosis of diabetes
- Complications associated with high blood glucose levels
PART 06: Pipeline portfolio
- Pipeline for new drug application (NDA) filings
- Pipeline for Phase III molecules
- Pipeline for Phase II molecules
- Pipeline for Phase I molecules
- Pipeline for pre-clinical stage molecules
- Pipeline for discovery stage molecules
PART 07: Market landscape
- Market overview
- Five forces analysis
PART 08: Overview of marketed products
- Synopsis of key diabetic drugs
- Marketed product profiles
PART 09: Market segmentation by type of disease
- Global type 1 diabetes market
- Global type 2 diabetes market
- Global gestational diabetes market
PART 10: Market segmentation by drug class
- Insulin therapies
- Non-insulin therapies
PART 11: Geographical segmentation
- Diabetic therapeutic market in Americas
- Diabetic therapeutic market in US
- Diabetic therapeutic market in EMEA
- Diabetic therapeutic market in Europe
- Diabetic therapeutic market in Germany
- Diabetic therapeutic market in UK
- Diabetic therapeutic market in France
- Diabetic therapeutic market in Italy
- Diabetic therapeutic market in Spain
- Diabetic therapeutic market in APAC
- Diabetic therapeutic market in China
- Diabetic therapeutic market in India
PART 12: Market drivers4
- Change in patient preference
- Focus on self-management of diabetes
- The strong potential of biologics
- Unmet medical needs and scope for DMDs
PART 13: Impact of drivers
PART 14: Market challenges
- Complex storage conditions and distribution policies for insulin
- Unpredictable outcomes on human due to lack of predictable animal models
- Gap in nation-level diabetes management plans
- Rising concerns in the scientific community
PART 15: Impact of drivers and challenges
PART 16: Market trends
- Focus on oral insulin therapies
- Growing technological integration fueling the market growth
- Focus on regenerative medicines
- Strong and diversified pipeline portfolio
PART 17: Vendor landscape8
- Competitive scenario
- Market analysis 2016
- Upcoming vendors for oral insulin therapies
- Oramed Pharmaceuticals
- Generex Biotechnology
- Other prominent vendors
PART 18: Key vendor analysis
- Novo Nordisk
- Sanofi
- Merck
- Eli Lilly
- AstraZeneca
PART 19: Appendix
PART 20: Explore Technavio